PATENT CLAIM ANALYSIS

Application Number: 16040324
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "081000"]

Abstract:
The disclosure is directed to methods of treating subjects infected with HIV, once daily, with single unit dosage forms that include darunavir (or a hydrate or solvate thereof), cobicistat, emtricitabine, and a tenofovir prodrug, or salt thereof.

Claim (Index 39):
The method of  claim 31 , wherein the subject does not exhibit an emergent resistance-associated mutation in an HIV virus after at least 24 weeks, at least 48 weeks, or at least 96 weeks, of once daily administration of the single unit dosage form.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 95.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15913750', '14679887', '11669547', '15406344', '14747621']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7964503028338946
- 35 USC 102 Novelty (BERT): 0.5269127165346985
- Combined Prediction Score: 0.7694965442039751
- Mean Citation Score: 309.5180220000001
- Max Citation Score: 312.86664
- Similarity Product: 174.46156880003932

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test